Article
Genetics & Heredity
Meral Kayikcioglu, Hasan Selcuk Ozkan, Burcu Yagmur, Selen Bayraktaroglu, Asli Tetik Vardarli
Summary: This article reports two cases of homozygous familial hypercholesterolemia with different treatment responses to lomitapide. The study aims to clarify the possibility of preventing the progression of atherosclerotic burden in patients with homozygous familial hypercholesterolemia through effective and safe reduction of LDL-C with low-dose lomitapide, and emphasizes the role of treatment adherence in therapy success.
FRONTIERS IN GENETICS
(2023)
Review
Cardiac & Cardiovascular Systems
Alexander Akhmedov, Tatsuya Sawamura, Chu-Huang Chen, Simon Kraler, Daria Vdovenko, Thomas F. Luscher
Summary: LOX-1, as a scavenger receptor, plays a crucial role in the development of atherosclerosis, with implications in various cell types, making it a promising diagnostic and therapeutic target for certain cardiovascular diseases.
EUROPEAN HEART JOURNAL
(2021)
Review
Cardiac & Cardiovascular Systems
Alexander Akhmedov, Tatsuya Sawamura, Chu-Huang Chen, Simon Kraler, Daria Vdovenko, Thomas F. Luescher
Summary: LOX-1, a scavenger receptor that promotes atherosclerotic plaque formation, plays a critical role in the development of cardiovascular diseases. Its expression in various cell types underscores its significance in disease progression, highlighting the potential for LOX-1 as a novel therapeutic target in CVDs prevention and treatment.
EUROPEAN HEART JOURNAL
(2021)
Review
Cell Biology
Mohammad Majharul Islam, Iryna Hlushchenko, Simon G. Pfisterer
Summary: This study aims to highlight that all steps from LDL internalization to receptor recycling are likely associated with dynamic membrane contact sites in which endosomes engage with the endoplasmic reticulum and other organelles. This has important implications for understanding diseases such as hypercholesterolemia.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Medicine, Research & Experimental
Mohammed Al Dubayee, Meral Kayikcioglu, Jeanine Roeters van Lennep, Nadia Hergli, Pedro Mata
Summary: Liver transplant did not achieve recommended LDL-C targets in most patients with HoFH, and the majority of patients still required post-transplant lipid-lowering therapy. Liver transplant was not curative in most of the patients with HoFH followed.
ADVANCES IN THERAPY
(2022)
Article
Biochemistry & Molecular Biology
David G. Thomas, Ying Wei, Alan R. Tall
Summary: The study assessed the pleiotropic effects of lipid trait genetic variants and conducted multivariable Mendelian randomization (MR) analysis in coronary artery disease. Results indicated that 30% of lipid trait genetic variants have effects on metabolic syndrome traits, yet the associations of LDL-C, HDL-C, TGs, BMI, T2D, and SBP with CAD remained independent and robust to adjustment for directional pleiotropy. MR at loci linked to direct effects on HDL-C and TGs suggested specific causal effects of these factors on CAD.
JOURNAL OF LIPID RESEARCH
(2021)
Article
Medicine, Research & Experimental
Qing Qi, Lijia Chen, Hongmei Sun, Na Zhang, Jing Zhou, Yang Zhang, Xinyan Zhang, Lisha Li, Dajin Li, Ling Wang
Summary: LDLR deficiency results in reduced bone mineral density of the tibial cancellous bone and promotes osteoclastogenesis. However, LDLR deficiency does not have a significant impact on the number of osteoblasts, and 17 beta-estradiol can inhibit osteoclastogenesis in vitro.
Article
Plant Sciences
Sunmin Woo, Hee-Sung Chae, Jinwoong Kim, Young-Won Chin
Summary: Several new compounds were isolated from Selaginella tamariscina, including a novel derivative, selapiginellin A, and a known compound, diselaginellin A. Selaginpulvilin U was found to regulate the mRNA expression of the LDLR gene.
JOURNAL OF NATURAL PRODUCTS
(2021)
Article
Chemistry, Multidisciplinary
Xiaomin Jiang, Wenbo Han, Jianqiao Liu, Jianming Mao, Morten J. Lee, Megan Rodriguez, Youyou Li, Taokun Luo, Ziwan Xu, Kaiting Yang, Marc Bissonnette, Ralph R. Weichselbaum, Wenbin Lin
Summary: This study reports a novel nanomedicine strategy for co-delivering combination chemotherapies to tumors using a designed nanoparticle system. The nanoparticles contain hydrophilic and hydrophobic prodrugs that target tumors actively through the LDL receptor. These nanoparticles selectively release the drugs in the acidic, esterase-rich, and reducing tumor microenvironments, leading to higher drug accumulations and significant tumor growth inhibition without causing serious side effects.
Article
Cardiac & Cardiovascular Systems
Feroz Ahmad, Robert D. Mitchell, Tom Houben, Angela Palo, Tulasi Yadati, Andrew J. Parnell, Ketan Patel, Ronit Shiri-Sverdlov, David S. Leake
Summary: The study shows that cysteamine can induce regression of atherosclerotic lesions in LDL receptor-deficient mice, improve lesion stability, reduce oxidized phospholipids, decrease liver lipid levels and expression of specific proteins and cytokines, as well as enhance skeletal muscle function. No changes were observed in plasma lipid concentrations. This suggests that lysosomal oxidation inhibition with antioxidants targeted at lysosomes may be a promising therapy for atherosclerosis in patients.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Oncology
Jia Gu, Neng Zhu, Hong-Fang Li, Tan-Jun Zhao, Chan-Juan Zhang, Duan-Fang Liao, Li Qin
Summary: The dysregulation of LDLR in cancer and its role in cholesterol homeostasis imbalance provides new therapeutic opportunities. LDLR plays a crucial role in cancer progression by modulating cholesterol balance and may serve as a novel target for anti-cancer drug development. The expression and regulation of LDLR vary in different types of cancer, suggesting the importance of personalized treatment approaches.
Article
Biochemistry & Molecular Biology
Jacek Jasiecki, Monika Targonska, Anna Janaszak-Jasiecka, Magdalena Chmara, Monika Zuk, Leszek Kalinowski, Krzysztof Waleron, Bartosz Wasag
Summary: Familial hypercholesterolemia (FH) is a genetic disorder caused by mutations in the LDL receptor (LDLR) gene, leading to an increased risk of cardiovascular diseases. This study developed a single-cell, kinetic, fluorescent LDL uptake assay to analyze the function of LDLR gene variants. It also established a human cell line with LDLR deficiency and a reporter system for studying LDLR gene transcriptional regulation, which can aid in drug testing for atherosclerosis therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Nutrition & Dietetics
Ewa Wieczorek, Agnieszka Cwiklinska, Agnieszka Kuchta, Barbara Kortas-Stempak, Anna Gliwinska, Maciej Jankowski
Summary: This study aimed to evaluate the impact of hypercholesterolemia and hypertriglyceridemia on the efficiency of lipoprotein lipase-mediated VLDL-triglyceride lipolysis, as well as the role of HDL in this process. The results showed that VLDL from patients with hypercholesterolemia and hypertriglyceridemia are more resistant to lipolysis, with HDL helping to enhance the efficiency of lipolysis in these groups.
Article
Biochemistry & Molecular Biology
Duanfang Cao, Bingting Ma, Ziyi Cao, Xinzheng Zhang, Ye Xiang
Summary: It is discovered that Semliki Forest virus (SFV) uses the very-low-density lipoprotein receptor (VLDLR) as a receptor during infection. The VLDLR binds multiple E1-DIII sites on SFV, with LA3 having the strongest binding affinity. The high-resolution structure shows that LA3 binds SFV E1-DIII through a small surface area, facilitating the binding of VLDLRs from different host species to SFV.
Article
Pharmacology & Pharmacy
Enchen Zhou, Zhuang Li, Hiroyuki Nakashima, Ahlam Choukoud, Sander Kooijman, Jimmy F. P. Berbee, Patrick C. N. Rensen, Yanan Wang
Summary: Accelerating lipolytic processing of VLDL by brown fat activation can further lower (V)LDL levels and reduce the risk of atherosclerosis.
PHARMACOLOGICAL RESEARCH
(2021)
